CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome
Helle Al-Hakem,Alex Y Doets,Amro Maher Stino,Sasha A Zivkovic,Henning Andersen,Hugh J Willison,David R Cornblath,Kenneth C Gorson,Zhahirul Islam,Quazi Deen Mohammad,Søren Hein Sindrup,Susumu Kusunoki,Amy Davidson,Carlos Casasnovas,Kathleen Bateman,James A L Miller,Bianca van den Berg,Christine Verboon,Joyce Roodbol,Sonja E Leonhard,Samuel Arends,Linda W G Luijten,Luana Benedetti,Satoshi Kuwabara,Peter Van den Bergh,Soledad Monges,Girolama A Marfia,Nortina Shahrizaila,Giuliana Galassi,Yann Pereon,Jan Bürmann,Krista Kuitwaard,Ruud P Kleyweg,Cintia Marchesoni,María J Sedano Tous,Luis Querol,Lorena Martín-Aguilar,Yuzhong Wang,Eduardo Nobile-Orazio,Simon Rinaldi,Angelo Schenone,Julio Pardo,Frederique H Vermeij,Waqar Waheed,Helmar C Lehmann,Volkan Granit,Beth Stein,Guido Cavaletti,Gerardo Gutiérrez-Gutiérrez,Fabio A Barroso,Leo H Visser,Hans D Katzberg,Efthimios Dardiotis,Shahram Attarian,Anneke J van der Kooi,Filip Eftimov,Paul W Wirtz,Johnny P A Samijn,H Jacobus Gilhuis,Robert D M Hadden,James K L Holt,Kazim A Sheikh,Noah Kolb,Summer Karafiath,Michal Vytopil,Giovanni Antonini,Thomas E Feasby,Catharina Faber,Hans Kramers,Mark Busby,Rhys C Roberts,Nicholas J Silvestri,Raffaella Fazio,Gert W van Dijk,Marcel P J Garssen,Jan Verschuuren,Thomas Harbo,Bart C Jacobs,IGOS Consortium,R A C Hughes,H P Hartung,L C de Koning,M Mandarakas,M van Woerkom,R C Reisin,S W Reddel,S T Hsieh,J M Addington,S Ajroud-Driss,L Alessandro,U A Badrising,G Balloy,I R Bella,T E Bertorini,R Bhavaraju-Sanka,M Bianco,T H Brannagan,K Brennan,C Briani,S Butterworth,C C Chao,S Chen,K G Claeys,M E Conti,J S Cosgrove,M C Dalakas,M Derejko,M M Dimachkie,A Echaniz-Laguna,C Fokke,T Fujioka,E A Fulgenzi,T García Sobrino,C J Gijsbers,J M Gilchrist,J M Goldstein,J Goodfellow,N A Goyal,S Grisanti,L Gutmann,M Htut,K Jellema,I Jericó Pascual,M C Jimeno-Montero,K Kaida,H Kerkhoff,M Khoshnoodi,L Kiers,M Kuwahara,J Y Kwan,S S Ladha,L Landschoff Lassen,V Lawson,E Lee Pan,M P T Lunn,H Manji,C Márquez Infante,E Martinez Hernandez,G Mataluni,M G Mattiazzi,C J McDermott,G D Meekins,G Morís de la Tassa,C Nascimbene,R J Nowak,P Orizaola,M Osei-Bonsu,A Pardal,E Pascual-Goñi,R M Pascuzzi,V Prada,M Pulley,I Rojas-Marcos,S A Rudnicki,G M Sachs,L Santoro,A Savransky,L Schwindling,Y Sekiguchi,C L Sommer,C-Y Tan,H Tankisi,P T Twydell,P van Damme,T van der Ree,R van Koningsveld,J D Varrato,V Vélez Santamaria,C Walgaard,Y Yamagishi,L Zhang,Mm,L Zhou
DOI: https://doi.org/10.1212/WNL.0000000000207282
IF: 9.9
2023-06-06
Neurology
Abstract:Background and objectives: To investigate CSF findings in relation to clinical and electrodiagnostic subtypes, severity, and outcome of Guillain-Barré syndrome (GBS) based on 1,500 patients in the International GBS Outcome Study. Methods: Albuminocytologic dissociation (ACD) was defined as an increased protein level (>0.45 g/L) in the absence of elevated white cell count (<50 cells/μL). We excluded 124 (8%) patients because of other diagnoses, protocol violation, or insufficient data. The CSF was examined in 1,231 patients (89%). Results: In 846 (70%) patients, CSF examination showed ACD, which increased with time from weakness onset: ≤4 days 57%, >4 days 84%. High CSF protein levels were associated with a demyelinating subtype, proximal or global muscle weakness, and a reduced likelihood of being able to run at week 2 (odds ratio [OR] 0.42, 95% CI 0.25-0.70; p = 0.001) and week 4 (OR 0.44, 95% CI 0.27-0.72; p = 0.001). Patients with the Miller Fisher syndrome, distal predominant weakness, and normal or equivocal nerve conduction studies were more likely to have lower CSF protein levels. CSF cell count was <5 cells/μL in 1,005 patients (83%), 5-49 cells/μL in 200 patients (16%), and ≥50 cells/μL in 13 patients (1%). Discussion: ACD is a common finding in GBS, but normal protein levels do not exclude this diagnosis. High CSF protein level is associated with an early severe disease course and a demyelinating subtype. Elevated CSF cell count, rarely ≥50 cells/μL, is compatible with GBS after a thorough exclusion of alternative diagnoses. Classification of evidence: This study provides Class IV evidence that CSF ACD (defined by the Brighton Collaboration) is common in patients with GBS.